Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Eli Lilly and Company
University of Utah
Fondazione Italiana Linfomi - ETS
Merck Sharp & Dohme LLC
University of Nebraska
Fudan University
Brown University
Sun Yat-sen University
Eli Lilly and Company
Abramson Cancer Center at Penn Medicine
Fondazione Italiana Linfomi - ETS
Ascentage Pharma Group Inc.
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Sun Yat-sen University
Medical College of Wisconsin
City of Hope Medical Center